Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Tom Langenaeken: Targeting Factor XI in Mechanical Heart Valve Thrombosis
Tom Langenaeken/LinkedIn
Jun 13, 2026, 14:41

Tom Langenaeken: Targeting Factor XI in Mechanical Heart Valve Thrombosis

Tom Langenaeken, Resident Cardiac Surgery at Catharina Ziekenhuis, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Vessels, Thrombosis & Haemostasis, adding:

“Our paper on Factor XI inhibition with gruticibart (AB023) for mechanical heart valve thrombosis is now published in Blood Vessels, Thrombosis & Haemostasis.

In a porcine pulmonary valve model, gruticibart achieved 100% valve patency without bleeding events at three months despite IV administration only once every 2 weeks.

A result we believe makes a compelling case for FXI as the target antithrombotic strategy in mechanical valve recipients.

This pilot study is the foundation for a larger follow-up series, which we are pleased to pursue with support from the Foundation for Cardiac Surgery.”

Title: Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model

Authors: Tom Langenaeken, Lennart Vanglabeke, Manon Van Hecke, Pieter De Meester, Tom Verbelen, Peter Verbrugghe, Filip Rega, Christina U Lorentz, Erik I Tucker, Bart Meuris

Tom Langenaeken: Targeting Factor XI in Mechanical Heart Valve Thrombosis

Stay updated on all scientific advances with Hemostasis Today.

 

Bart Meuris Christina U Lorentz Erik I Tucker Factor XI Filip Rega Health Hematology Hemostasis Hemostasis News Hemostasis Today Lennart Vanglabeke Manon Van Hecke mechanical heart valve Medicine Peter Verbrugghe Pieter De Meester thrombosis Tom Langenaeken Tom Verbelen
NewsFeed